Skip to main content

Table 2 Markers with independent prognostic value (Glioblastoma and Anaplastic Astrocytoma patients only)

From: Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial

Marker

N

HR (95% CI)

p-value

Overall p-value

Chromosome 1

    

 Normal

153

-

 

0.358

 Trisomy

4

0.92 (0.29-2.92)

0.885

 

 Any other abnormality

104

1.22 (0.93-1.59)

0.157

 

1p status

    

 Normal

178

-

 

0.828

 Total loss of 1p

3

1.00 (0.24-4.10)

0.996

 

 Any other abnormality

80

1.09 (0.82-1.45)

0.537

 

1p36 status

    

 Normal

192

-

 

0.646

 Loss of 1 copy

53

1.05 (0.75-1.45)

0.787

 

 Loss of both copies

6

1.75 (0.76-4.05)

0.187

 

 Any other abnormality

10

1.18 (0.57-2.42)

0.654

 

Chromosome 7

    

 Normal

58

-

 

0.029

 Monosomy

1

0.44 (0.06-3.35)

0.426

 

 Trisomy

145

1.64 (1.11-2.42)

0.014

 

 Any other abnormality

57

1.17 (0.77-1.79)

0.455

 

Chromosome 10

    

 Normal

38

-

 

0.006

 Monosomy

150

1.41 (0.91-2.19)

0.127

 

 10q partial deletion

59

0.76 (0.48-1.21)

0.241

 

 Any other abnormality

14

1.24 (0.58-2.65)

0.583

 

PTEN

    

 Normal

80

-

 

0.001

 Hemizygous deletion

172

1.85 (1.32-2.60)

<0.001

 

 Homozygous deletion

9

1.31 (0.62-2.81)

0.480

 

MGMT

    

 Normal

43

-

 

0.776

 Hemizygous deletion

217

1.05 (0.72-1.54)

0.797

 

 Homozygous deletion

1

2.22 (0.30-16.56)

0.438

 

Chromosome 19

    

 Normal

161

-

 

0.565

 Monosomy

4

1.91 (0.69-5.25)

0.210

 

 Trisomy

52

1.14 (0.82-1.60)

0.442

 

 Any other abnormality

44

0.95 (0.66-1.36)

0.772

 

19q status

    

 Normal

166

-

 

0.754

 Total loss of 19q

3

1.10 (0.27-4.55)

0.898

 

 Any other abnormality

92

1.11 (0.84-1.47)

0.454

 

19q13 status

    

 Normal

166

-

 

0.643

 Loss of 1 copy

23

0.99 (0.60-1.62)

0.968

 

 Any other abnormality

72

1.15 (0.85-1.55)

0.355

 

EGFR

    

 Normal

157

-

 

0.013

 Amplified

104

1.42 (1.08-1.87)

0.013

 

CDKN2A

    

 Normal

111

-

 

0.771

 Hemizygous deletion

78

1.09 (0.79-1.51)

0.587

 

 Homozygous deletion

72

1.12 (0.80-1.58)

0.500

 

MDM2

    

 Normal

239

-

 

0.591

 Amplified

22

1.13 (0.72-1.78)

0.586

 

CDK4

    

 Normal

233

-

 

0.083

 Amplified

28

1.46 (0.97-2.21)

0.070

 

PDGFRA

    

 Normal

244

-

 

0.998

 Amplified

17

1.00 (0.60-1.68)

0.997

 

Chromosome 13

    

 Normal

184

-

 

0.760

 Monosomy

37

1.15 (0.79-1.68)

0.460

 

 Trisomy

1

0.86 (0.12-6.34)

0.886

 

 Partial deletion

28

1.34 (0.85-2.11)

0.207

 

 Any other abnormality

11

1.10 (0.53-2.28)

0.808

 

RB1 gene status

    

 Normal

195

-

 

0.469

 Hemizygous deletion

65

1.22 (0.89-1.66)

0.221

 

 Homozygous deletion

1

0.86 (0.12-6.26)

0.878

 

RB1 pathway

    

 Normal

71

-

 

0.061

 Abnormal

190

1.35 (0.98-1.87)

0.066

 

TP53 mutation

    

 No

47

-

 

0.296

 Yes

83

0.80 (0.53-1.21)

0.293

 

p53 pathway

    

 Normal

12

-

 

0.265

 Abnormal

207

1.46 (0.73-2.91)

0.289

 

IDH1

    

 Normal

198

-

 

<0.001

 Mutation

77

0.38 (0.26-0.56)

<0.001

 

MGMT methylation

    

 <10%

71

-

 

<0.001

 ≥10%

204

0.45 (0.34-0.60)

<0.001

 
Back to article page

Acta Neuropathologica Communications

ISSN: 2051-5960

Contact us